- Locus Cell has signed its first international Phase III CDMO Memorandum of Understanding with Cambium Bio to handle contract development and manufacturing of Elate Ocular®, a dry eye disease therapy.
- The agreement covers all international clinical and commercial manufacturing outside the Middle East and Europe, reinforcing Locus Cell’s role in the global pharmaceutical supply chain.
Locus Cell, a regenerative medicine CDMO in Taiwan, has entered a Memorandum of Understanding (MOU) with Australia-based Cambium Bio to provide contract development and manufacturing for Elate Ocular®. The therapy, currently in Phase III clinical trials, targets dry eye disease and is being tested in Taiwan, the U.S., and Australia.
The technology for Elate Ocular® originates from Cambium Bio’s parent company, Zheng Yang Biomedical Technology Co., Ltd. Under the agreement, Locus Cell will manage all international clinical and commercial manufacturing outside the Middle East and Europe. Cambium has separately licensed rights for those regions to France’s Benta SAS.
“This MOU represents our first Phase III international CDMO project, a strong vote of confidence in our Zhubei smart GMP facility. It proves our vision of ‘rooted in Taiwan, serving global clients’ is achievable. By integrating FDA requirements—including electronic batch records, traceability, environmental monitoring, and data integrity—we are ready to seamlessly support global pharmaceutical partners.”
Jiunn-Rong Chiou, Chairman of Locus Cell
Cambium Bio CEO Karolis Rosickas noted that Locus Cell’s Zhubei GMP facility meets FDA and GMP standards and is among the few in Asia capable of both clinical and commercial production. He highlighted that its digital-enabled operations offer flexibility, lower costs, and quality assurance.
This collaboration marks a strategic milestone for Locus Cell, positioning the company as a key international CDMO partner and supporting the global expansion of Elate Ocular®. The partnership leverages the company’s smart GMP facility to strengthen its role in the contract manufacturing landscape.
